PRKAA1 and adenocarcinoma: A retrospective study from Cleveland Clinic observed that diabetic patients with lung cancer, who were previously exposed to metformin and/or another class of anti-diabetic drugs (thiazolidenediones: also known to activate AMPK), are less likely to present with metastatic disease, are more likely to present with an adenocarcinoma, and they may survive longer [132].